Literature DB >> 23045169

The Barth Syndrome Registry: distinguishing disease characteristics and growth data from a longitudinal study.

Amy E Roberts1, Connie Nixon, Colin G Steward, Kimberly Gauvreau, Melissa Maisenbacher, Matthew Fletcher, Judith Geva, Barry J Byrne, Carolyn T Spencer.   

Abstract

Barth syndrome (BTHS); MIM accession # 302060) is a rare X-linked recessive cardioskeletal mitochondrial myopathy with features of cardiomyopathy, neutropenia, and growth abnormalities. The objectives of this study were to further elucidate the natural history, clinical disease presentation, and course, and describe growth characteristics for males with BTHS. Patients with a confirmed genetic diagnosis of BTHS are referred to the BTHS Registry through the Barth Syndrome Foundation, self-referral, or physician referral. This study is based on data obtained from 73 subjects alive at the time of enrollment that provided self-reported and/or medical record abstracted data. The mean age at diagnosis of BTHS was 4.04 ± 5.45 years. While the vast majority of subjects reported a history of cardiac dysfunction, nearly 6% denied any history of cardiomyopathy. Although most subjects had only mildly abnormal cardiac function by echocardiography reports, 70% were recognized as having cardiomyopathy in the first year of life and 12% have required cardiac transplantation. Of the 73 enrolled subjects, there have been five deaths. Growth curves were generated demonstrating a shift down for weight, length, and height versus the normative population with late catch up in height for a significant percentage of cases. This data also confirms a significant number of patients with low birth weight, complications in the newborn period, failure to thrive, neutropenia, developmental delay of motor milestones, and mild learning difficulties. However, it is apparent that the disease manifestations are variable, both over time for an individual patient and across the BTHS population.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23045169     DOI: 10.1002/ajmg.a.35609

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  47 in total

1.  Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.

Authors:  Catherine H Le; Lindsay G Benage; Kalyn S Specht; Lance C Li Puma; Christopher M Mulligan; Adam L Heuberger; Jessica E Prenni; Steven M Claypool; Kathryn C Chatfield; Genevieve C Sparagna; Adam J Chicco
Journal:  J Biol Chem       Date:  2020-07-14       Impact factor: 5.157

Review 2.  Pediatric Cardiomyopathies.

Authors:  Teresa M Lee; Daphne T Hsu; Paul Kantor; Jeffrey A Towbin; Stephanie M Ware; Steven D Colan; Wendy K Chung; John L Jefferies; Joseph W Rossano; Chesney D Castleberry; Linda J Addonizio; Ashwin K Lal; Jacqueline M Lamour; Erin M Miller; Philip T Thrush; Jason D Czachor; Hiedy Razoky; Ashley Hill; Steven E Lipshultz
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

Review 3.  TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.

Authors:  Anders O Garlid; Calvin T Schaffer; Jaewoo Kim; Hirsh Bhatt; Vladimir Guevara-Gonzalez; Peipei Ping
Journal:  Gene       Date:  2019-10-21       Impact factor: 3.688

4.  Atypical Clinical Presentations of TAZ Mutations: An Underdiagnosed Cause of Growth Retardation?

Authors:  Charlotte Thiels; Martin Fleger; Martina Huemer; Richard J Rodenburg; Frederic M Vaz; Riekelt H Houtkooper; Tobias B Haack; Holger Prokisch; René G Feichtinger; Thomas Lücke; Johannes A Mayr; Saskia B Wortmann
Journal:  JIMD Rep       Date:  2016-01-03

5.  CLPB variants associated with autosomal-recessive mitochondrial disorder with cataract, neutropenia, epilepsy, and methylglutaconic aciduria.

Authors:  Carol Saunders; Laurie Smith; Flemming Wibrand; Kirstine Ravn; Peter Bross; Isabelle Thiffault; Mette Christensen; Andrea Atherton; Emily Farrow; Neil Miller; Stephen F Kingsmore; Elsebet Ostergaard
Journal:  Am J Hum Genet       Date:  2015-01-15       Impact factor: 11.025

6.  A novel mutation in TAZ causes mitochondrial respiratory chain disorder without cardiomyopathy.

Authors:  Nurun N Borna; Yoshihito Kishita; Kaori Ishikawa; Kazuto Nakada; Jun-Ichi Hayashi; Yoshimi Tokuzawa; Masakazu Kohda; Hiromi Nyuzuki; Yzumi Yamashita-Sugahara; Takashi Nasu; Atsuhito Takeda; Kei Murayama; Akira Ohtake; Yasushi Okazaki
Journal:  J Hum Genet       Date:  2017-01-26       Impact factor: 3.172

Review 7.  Inborn errors of metabolism in the biosynthesis and remodelling of phospholipids.

Authors:  Saskia B Wortmann; Marc Espeel; Ligia Almeida; Annette Reimer; Dennis Bosboom; Frank Roels; Arjan P M de Brouwer; Ron A Wevers
Journal:  J Inherit Metab Dis       Date:  2014-09-02       Impact factor: 4.982

8.  Clinical Characteristics and Outcomes of Cardiomyopathy in Barth Syndrome: The UK Experience.

Authors:  Sok-Leng Kang; Jonathan Forsey; Declan Dudley; Colin G Steward; Beverly Tsai-Goodman
Journal:  Pediatr Cardiol       Date:  2015-09-04       Impact factor: 1.655

9.  A Novel Exonic Splicing Mutation in the TAZ (G4.5) Gene in a Case with Atypical Barth Syndrome.

Authors:  Yuxin Fan; Jon Steller; Iris L Gonzalez; Wim Kulik; Michelle Fox; Richard Chang; Brandy A Westerfield; Anjan S Batra; Raymond Yu Jeang Wang; Natalie M Gallant; Liana S Pena; Hu Wang; Taosheng Huang; Sunita Bhuta; Daniel J Penny; Edward R McCabe; Virginia E Kimonis
Journal:  JIMD Rep       Date:  2013-04-19

10.  AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine Knockout Model of Barth Syndrome.

Authors:  Suya Wang; Yifei Li; Yang Xu; Qing Ma; Zhiqiang Lin; Michael Schlame; Vassilios J Bezzerides; Douglas Strathdee; William T Pu
Journal:  Circ Res       Date:  2020-03-09       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.